Related Articles
First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer
Pathotropic nanoparticles for cancer gene therapy Rexin-G™ IV: Three-year clinical experience
Nanotechnology blooms, at last (Review)
Rexin‑G®, a tumor‑targeted retrovector for malignant peripheral nerve sheath tumor: A case report
Le morte du tumour: Histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes